HERON THERAPEUTICS, INC. /DE/

The company is a commercial-stage biotechnology firm focused on developing and commercializing therapeutic products for acute care and oncology patients. Its acute care product line includes ZYNRELEF, a dual-acting extended-release local anesthetic combining bupivacaine and meloxicam for postoperative pain management, and APONVIE, an intravenous formulation of aprepitant used to prevent postoperative nausea and vomiting. Its oncology offerings consist of CINVANTI and SUSTOL, which are injectable therapies designed to prevent acute and delayed chemotherapy-induced nausea and vomiting. The company markets these treatments in the United States through specialty distributors and full-line wholesalers that supply healthcare providers and hospital systems.

The company operates primarily within the United States, maintaining a domestic sales and marketing team of 78 employees as of December 31, 2025. It does not own or operate manufacturing facilities, depending on third-party contract manufacturers for the production of clinical and commercial supplies. The provided excerpt does not state the location of the company's corporate headquarters.

Summary of the business section of Heron Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we employed 128 full-time employees, 78 of whom are involved in sales and marketing activities, 7 of whom are involved in research and development activities and 43 of whom are involved in general and administrative activities.”